Medtronic's MiniMed IPO Set for March 2026 to Enhance Diabetes Management Solutions

### Medtronic’s Commitment to Innovation and Growth Evident through Upcoming MiniMed IPO

Medtronic plc, a global leader in healthcare technology based in Galway, Ireland, demonstrates its commitment to innovation and market growth with the forthcoming initial public offering (IPO) of its subsidiary MiniMed Group, Inc. Scheduled to trade on the Nasdaq Global Select Market starting March 6, 2026, the IPO includes 28 million shares priced at $20.00 each. This strategic move aims to bolster MiniMed's position as a pioneer in insulin delivery solutions aimed at enhancing diabetes management for patients around the world. As a recognized contributor to the global healthcare landscape, Medtronic continues to focus on creating value through its subsidiaries, underscoring its commitment to addressing critical health challenges.

With a massive workforce of over 95,000 spanning more than 150 countries, Medtronic seeks to alleviate pain and restore health through its extensive portfolio that covers a variety of medical technologies and therapies addressing 70 distinct health conditions. The upcoming IPO offers a fresh avenue for MiniMed to secure funding that will be utilized for general corporate purposes, including repaying intercompany debt to Medtronic and compensating for transferred assets from the separation of the two companies. Following the offering, Medtronic will maintain a substantial ownership stake in MiniMed, supporting the interconnected growth of both entities and enhancing their collective impact in the healthcare industry.

The IPO is managed by a robust underwriting team including Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley, providing the necessary support and expertise to navigate the public market landscape. This transaction not only reflects Medtronic's strategic vision but also positions MiniMed for accelerated growth in the insulin delivery sector, a critical component of diabetes management. As health challenges become increasingly complex, Medtronic’s move to empower MiniMed through this IPO is a definitive step toward nurturing innovation and improving patient outcomes.

In addition to the MiniMed IPO, Medtronic has recently announced a cash dividend of $0.71 per ordinary share for the fourth quarter of fiscal year 2026. This dividend declaration aligns with the company's long-standing commitment to enhancing shareholder value, marking 48 consecutive years of increased annual dividend payments, a testament to its stability and growth in the healthcare market.

As Medtronic continues to navigate the complexities of the healthcare landscape, it emphasizes the importance of insight-driven care and transformative technologies. The company encourages stakeholders to engage further through their online platforms, ensuring transparency and accessibility in their operations.